Skip to content
Search

Latest Stories

Covid boosters to be offered to over 40s

Britain's booster programme for Covid-19 vaccinations is set to be expanded following advice from scientists.

The government's Joint Committee on Vaccination and Immunization (JCVI) said today (November 15) that all healthy adults aged 40-49 should be offered a booster, six months after their second dose.


Previously, the booster programme was limited to those aged 50 and over, and the clinically vulnerable.

So far, some 12.6 million people have had a booster dose.

The latest advice comes after the UK Health Security Agency released data from a real-world study which found the booster gave over 90 per cent protection against symptomatic Covid-19 for people aged 50 years and older.

The JCVI also said that 16 and 17 year olds, who were initially offered only a single dose, should now get a second.

Professor Wei Shen Lim, chair, Covid-19 immunisation, JCVI said: “Booster vaccine doses in more vulnerable adults, and second vaccine doses in 16 – 17 year olds are important ways to increase our protection against Covid-19 infection and severe disease. These vaccinations will also help extend our protection into 2022.”

Following JCVI advise the UK has been using either the Pfizer-BioNTech vaccine, or the Moderna vaccine in the booster rollout.

The Medicines and Healthcare products Regulatory Agency (MHRA) has maintained that booster doses are safe and side-effects, if any, are either a sore arm or flu-like symptoms.

MHRA chief executive Dr June Raine welcomed JCVI's announcement on the extension of the booster campaign to 40-49 year olds.

"This further strengthens our ability to ensure people are protected against Covid-19 and saves lives. Our proactive monitoring of the safety of booster doses does not raise any new concerns," she said.

More For You

Pharmacist Support calls for birthday donations to meet rising demand for mental health services

More and more pharmacy professionals are reaching out for help, said Danielle Hunt.

Pharmacist Support's birthday appeal: Donate to address growing mental health demand

Pharmacist Support – the independent charity dedicated to the pharmacy profession – is celebrating 184 years of service with the launch of a special birthday donations appeal.

On 15 April, the charity is urging individuals and organisations across the sector to support its campaign to raise vital funds to meet the increasing demand for its mental health and wellbeing services.

Keep ReadingShow less
Prostate cancer: At-home saliva test could save NHS £500 million annually

PRS saliva test can identify prostate cancer that was missed by an MRI scan

Photo credit: gettyimages

Prostate cancer: Spit test better than blood test in spotting men at highest risk

A simple at-home spit test could help detect prostate cancer earlier, saving the NHS around £500 million a year, according to new research published in the New England Journal of Medicine.

Funded by the National Institute for Health and Care Research (NIHR), the study found that the DNA-based saliva test was more accurate than the current prostate-specific antigen (PSA) blood test in identifying men at risk of developing prostate cancer.

Keep ReadingShow less
RPS launches innovative new learning resources for members

With RPS Learn, pharmacists can develop a new skill or improve their understanding of practice or a clinical topic.

Gettyimages

RPS launches new learning resources to boost career development for members

The Royal Pharmaceutical Society (RPS) has launched a new online learning platform designed to support the practice, development and career advancement of its members.

The new platform, called RPS Learn, offers a diverse range of bite-size learning content, available on-demand, catering to all levels — from introductory to advanced and specialist —combining new content with RPS's renowned expertise in education and training to achieve excellence for learners.

Keep ReadingShow less
NICE approves AstraZeneca’s twice-a-day tablet ‘capivasertib’ for advanced breast cancer

HR-positive, HER2-negative advanced breast cancer is currently incurable, and treatment aims to slow progression and prolong life

Gettyimages

NICE approves twice-a-day tablet for advanced breast cancer

Every year, thousands of people with hormone receptor (HR)-positive HER2-negative breast cancer could benefit from a new twice-a-day tablet, now set to be funded immediately through the Cancer Drugs Fund.

The National Institute for Health and Care Excellence (NICE) has approved the use of capivasertib (also known as Truqap), in combination with fulvestrant, as an option for around 1,100 adults with HR-positive HER2-negative breast cancer that has certain genetic mutations and has spread.

Keep ReadingShow less
ABPI and government fast-track VPAG scheme review to address high medicine payment rates

The 2025 VPAG payment rate for newer medicines has been set at 22.9 per cent.

Photo credit: gettyimages

Review of 2024 VPAG scheme to be completed by June

The Association of the British Pharmaceutical Industry (ABPI) and the government have agreed to bring forward a planned review of the 2024 Voluntary Scheme for Branded Medicines Pricing, Access, and Growth (VPAG), originally scheduled for autumn 2025.

The review is expected to be completed in June 2025, aligning with the anticipated release of the government’s 10-year NHS Plan and the Life Sciences Sector Plan as part of the broader industry strategy this summer.

Keep ReadingShow less